VX 765 - CAS# 273404-37-8 size:2mg solid BRN1299325

BRN1299325

2140807-17-4

As dysregulation of the UPR has been implicated in a variety of cell degenerative and neoplastic disorders

RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region

InChi: InChI=1S/C6H9NO5/c1-11-4(8)3-7-5(9)6(10)12-2/h3H2

VX 765 - CAS# 273404-37-8 size:2mg solid BRN1299325VX 765, CAS No. 273404 37 8, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL 1b and IL 18. VX 765 has been shown to inhibit acute seizures in preclinical models. In addition, VX 765 has shown activity in preclinical models of chronic epilepsy. VX 765 had been dosed in over 100 patients in phase I and phase IIa clinical trials relating to other diseases, including a 28 day phase IIa clinical trial in